KMDA Stock Overview
Manufactures and sells plasma-derived protein therapeutics. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for KMDA from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Kamada Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪22.00 |
| 52 Week High | ₪23.90 |
| 52 Week Low | ₪17.95 |
| Beta | 0.24 |
| 1 Month Change | 1.43% |
| 3 Month Change | 9.89% |
| 1 Year Change | 1.10% |
| 3 Year Change | 3.68% |
| 5 Year Change | -7.17% |
| Change since IPO | 67.30% |
Recent News & Updates
Here's Why Shareholders May Want To Be Cautious With Increasing Kamada Ltd.'s (TLV:KMDA) CEO Pay Packet
Dec 05
Solid Earnings Reflect Kamada's (TLV:KMDA) Strength As A Business
Nov 20Recent updates
Here's Why Shareholders May Want To Be Cautious With Increasing Kamada Ltd.'s (TLV:KMDA) CEO Pay Packet
Dec 05Solid Earnings Reflect Kamada's (TLV:KMDA) Strength As A Business
Nov 20Kamada's (TLV:KMDA) Earnings Are Of Questionable Quality
Mar 14Kamada Ltd. (TLV:KMDA) Held Back By Insufficient Growth Even After Shares Climb 29%
Dec 30Some Shareholders May find It Hard To Increase Kamada Ltd.'s (TLV:KMDA) CEO Compensation This Year
Dec 22Is Kamada (TLV:KMDA) Using Too Much Debt?
Jan 26We Discuss Why Kamada Ltd.'s (TLV:KMDA) CEO Compensation May Be Closely Reviewed
Dec 16Investors Who Bought Kamada (TLV:KMDA) Shares Five Years Ago Are Now Up 38%
Mar 01Is Kamada Ltd. (TLV:KMDA) Popular Amongst Insiders?
Feb 08Is Weakness In Kamada Ltd. (TLV:KMDA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Jan 21
Kamada Ltd. (TLV:KMDA) Shares Could Be 42% Below Their Intrinsic Value Estimate
Jan 03How Many Kamada Ltd. (TLV:KMDA) Shares Have Insiders Sold, In The Last Year?
Dec 15Are Kamada's (TLV:KMDA) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Nov 29Shareholder Returns
| KMDA | IL Biotechs | IL Market | |
|---|---|---|---|
| 7D | 5.7% | 3.5% | -0.2% |
| 1Y | 1.1% | -23.5% | 23.4% |
Return vs Industry: KMDA exceeded the IL Biotechs industry which returned -23.5% over the past year.
Return vs Market: KMDA underperformed the IL Market which returned 23.4% over the past year.
Price Volatility
| KMDA volatility | |
|---|---|
| KMDA Average Weekly Movement | 3.2% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in IL Market | 8.2% |
| 10% least volatile stocks in IL Market | 3.0% |
Stable Share Price: KMDA has not had significant price volatility in the past 3 months compared to the IL market.
Volatility Over Time: KMDA's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 378 | Amir London | www.kamada.com |
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers.
Kamada Ltd. Fundamentals Summary
| KMDA fundamental statistics | |
|---|---|
| Market cap | ₪1.26b |
| Earnings (TTM) | ₪57.31m |
| Revenue (TTM) | ₪577.68m |
22.1x
P/E Ratio2.2x
P/S RatioIs KMDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KMDA income statement (TTM) | |
|---|---|
| Revenue | US$158.38m |
| Cost of Revenue | US$91.03m |
| Gross Profit | US$67.35m |
| Other Expenses | US$51.64m |
| Earnings | US$15.71m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.27 |
| Gross Margin | 42.52% |
| Net Profit Margin | 9.92% |
| Debt/Equity Ratio | 0% |
How did KMDA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 02:10 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kamada Ltd. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Fein | H.C. Wainwright & Co. |
| Anthony Petrone | Jefferies LLC |
| David Lewis | Morgan Stanley |